Navigation Links
Intellect Neurosciences, Inc. to Present Data on Alzheimer's Vaccine at 13th International Congress of Immunology Conference

Chimeric Peptide Vaccine Aims to Use Memory Imprint to Yield a Strong and

Highly Specific Immune Response

NEW YORK, Aug. 20 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS) a biopharmaceutical company focused on development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and related disorders, announced today that Dr. Rachel Eren, Vice President Research, will present new data regarding the Company's RECALL-VAX(TM) chimeric peptide vaccine technology at the 13th International Congress of Immunology on Thursday, August 23, 2007 in Rio de Janeiro, Brazil. Mice immunized with RECALL-VAX(TM) constructs mounted a robust and highly specific immune response against beta-amyloid. The data demonstrate for the first time that a "free-end specific" polyclonal response to beta-amyloid can be achieved, potentially overcoming an important safety concern for active immunization of Alzheimer's disease patients.

"We are pleased with our scientists' progress in establishing important proof of principle for this novel and proprietary vaccine technology, which is designed to make active immunization safe and practical for treating Alzheimer's patients," commented Dr. Daniel Chain, Intellect's Chairman and CEO. He added: "We believe that RECALL-VAX(TM) could potentially be used prophylactically to prevent or delay the onset of Alzheimer's disease in elderly people."

"There are multiple challenges in developing a means to safely immunize elderly individuals and avoid the failures encountered in previous clinical trials sponsored by major pharmaceutical companies," commented Professor Benjamin Chain at the Department of Immunology and Molecular Pathology, Windeyer Institute of Medical Sciences, University College London. Professor Chain added: "The major challenges are the need to: (i) mount a robust immune response when the immune system has become senescent as the result of age; (ii) avoid autoimmune reactions; and (iii) ensure that the antibodies generated do not interfere with the normal physiological functions of the Amyloid Precursor Protein. RECALL-VAX(TM) is specifically designed to address these challenges." Professor Chain, the brother of Dr. Daniel Chain, Intellect's Chairman and CEO, is the inventor of RECALL-VAX(TM) and a member of the Company's Scientific Advisory Board.

About Intellect's RECALL-VAX(TM) technology

The key to inactivation of the beta-amyloid toxin by vaccination is to stimulate a strong antibody immune response that specifically targets the toxin. The proprietary RECALL-VAX(TM) technology combines a short fragment of beta-amyloid with part of the tetanus toxoid, against which most people have been vaccinated, to provide B and T-helper epitopes, respectively, while specifically targeting the beta-amyloid toxin. This combination increases the likelihood of generating a robust immune response as a result of the memory imprint created by tetanus toxoid without the danger of contamination from potentially harmful human beta-amyloid T-cell epitopes. The short fragments of beta-amyloid used in RECALL-VAX(TM) ensure that only the toxin, and not the protein from which it is derived, is targeted by the antibodies, and because of their short length, the fragments are incapable of provoking an autoimmune response.

About Alzheimer's disease

Alzheimer's disease, the most common form of dementia, is characterized by progressive loss of memory and cognition, ultimately leading to complete debilitation and death. A hallmark feature of Alzheimer's pathology is the presence of insoluble protein deposits known as beta-amyloid on the surface of nerve cells, which results from the accumulation of soluble beta-amyloid in the brain. The effects of the disease are devastating to the patients as well as the caregivers, with significant associated health care costs. It is estimated that there are over 12 million people suffering from Alzheimer's disease in the major markets worldwide with the number increasing as the global population ages. Currently marketed drugs transiently affect some of the symptoms of the disease, but there are no drugs on the market today that slow or arrest the progression of the disease. These symptomatic drugs are projected to generate approximately $4 billion in sales by 2008, indicating both the size of the market and the demand for effective treatment beyond symptomatic improvements.

About Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. is a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and related disorders. The Company has a broad proprietary immunotherapy platform for both active and passive (using humanized monoclonal antibodies) immunization against Alzheimer's disease. Also, Intellect has recently completed Phase I clinical trials for OXIGON(TM), a unique antioxidant and anti-amyloid compound that has potential to treat Alzheimer's disease and other disorders.

For additional information, please visit

SOURCE Intellect Neurosciences, Inc.

Copyright©2007 PR Newswire.

Related biology technology :

1. Inline intellectual property raises legal issues
2. Intellectual Property: Are you an infringer?
3. Starting a tech business? Step 1 is minding the intellectual property
4. Protect your intellectual property before its too late
5. Protecting your intellectual property in overseas markets
6. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
7. Wisconsin firms to present at Cleantech venture capital event
8. New Sonic Foundry search engine finds words, phrases in video presentations
9. Lone Wisconsin firm to present at InvestMidwest
10. Sonic Foundry creates search engine for 7,000 expert video presentations
11. InvestMidWest calls for business presentations
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... ... relationship marketing company specializing in scientifically backed, age-defying products, is featured as ... which highlights the exponential success and unrivaled opportunities that Nerium provides. Success ...
(Date:12/1/2015)... Dallas, Texas (PRWEB) , ... December 01, 2015 ... ... its annual global meeting this month and Dr. J. Kyle Mathews ... worldwide.” This includes the new single site hysterectomy. , An experienced urogynecologist, founder ...
(Date:11/30/2015)... ... , ... Global Stem Cells Group announced that its scientific team ... isolating adipose-derived stem cells. The announcement starts a new phase toward launching the simple, ... component of the lipoaspirate obtained from liposuction of excess adipose tissue. , Lipoaspirate, ...
(Date:11/30/2015)... Dec. 1, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), ... joined the American Business Act on Climate Pledge, alongside more ... standing with the Obama Administration to demonstrate an ongoing commitment ... outcome to the COP21 Paris climate ... Sarnia, Canada . --> BioAmber ...
Breaking Biology Technology:
(Date:10/29/2015)... 2015 NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... a leading marketplace to discover and buy innovative ... wallet on StackSocial for this holiday season.   ... "Company"), a biometric authentication company focused on the ...
(Date:10/27/2015)... -- In the present market scenario, security is one ... verticals such as banking, healthcare, defense, electronic gadgets, and ... secure & simplified access control and growing rate of ... bank accounts, misuse of users, , and so on. ... and smartphones are expected to provide potential opportunities for ...
(Date:10/27/2015)... Oct. 27, 2015 Synaptics Inc. (NASDAQ: SYNA ... that Google has adopted the Synaptics ® ClearPad ... to power its newest flagship smartphones, the Nexus 5X ... --> --> Synaptics ... provide strategic collaboration in the joint development of next ...
Breaking Biology News(10 mins):